KRM Ayurveda was incorporated on April 17, 2020. The company operates a network of six hospitals and five clinics across India and has an international presence through telemedicine consultations and sales. While it began as a kidney care provider, it now offers specialized treatments for multiple health disorders and trades in Ayurvedic medicines, oils, and supplements across wellness and healthcare segments
| Bidding Dates |
|---|
| 21 Jan 2026 - 23 Jan 2026 |
| Subscription |
|---|
| 64.25x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹2,56,000 | 2 | 2 | 1000 | 5.7 M | ₹128 - ₹135 | 67.28 % | ₹734.7 M - ₹774.9 M | RHP DOC |
KRM Ayurveda IPO SUBSCRIPTION STATUS
23 Jan '26KRM Ayurveda IPO overall subscription rate was 64.25 times the total available shares
KRM Ayurveda IPO retail subscription rate was 66.85 times in the retail segment
KRM Ayurveda IPO non-institutional investor subscription rate was 168.59 times in the non-institutional investor category
KRM Ayurveda IPO Qualified Institutional Bidder subscription rate was 31.13 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
23 Jan 2026 (Day 3) | 66.85x | 168.59x | 31.13x |
22 Jan 2026 (Day 2) | 5.74x | 8.03x | - |
21 Jan 2026 (Day 1) | 2.02x | 2.05x | - |
KRM Ayurveda FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| H1FY26 | 48.4 | 8.1 | 3.0 | 2.5 | 26.54% |
| FY25 | 76.6 | 12.1 | 0.0 | -4.8 | 25.0% |
| FY24 | 67.2 | 3.4 | -0.9 | -1.4 | 10.9% |
| FY23 | 89.3 | 7.6 | 3.5 | -19.5 | 12.4% |
KRM Ayurveda IPO SUBSCRIPTION STATUS DETAILS
KRM Ayurveda had 5.7 M shares on offer
KRM Ayurveda IPO offer price was in the range ₹128 - ₹135
KRM Ayurveda IPO minimum Investment was ₹256000
KRM Ayurveda IPO issue size was ₹ 734.7 M - ₹ 774.9 M
KRM Ayurveda had a minimum lot size of 1000 Shares per application
KRM Ayurveda NUMBER OF SHARES ON OFFER
KRM Ayurveda IPO IMPORTANT DATES
| Issue Open Date | 21 Jan 2026 |
| Issue close Date | 23 Jan 2026 |
| Allotment Date | 27 Jan 2026 |
| Refund Date | 28 Jan 2026 |
| Demat Account Credit Date | 28 Jan 2026 |
| Listing Date | 29 Jan 2026 |
| Listing on Exchange(s) | NSE |
| KRM Ayurveda Allotment Status | Exchange/ Registrar |
KRM Ayurveda IPO subscription opened on 21 Jan 2026, and closed on 23 Jan 2026
IPO allotment for KRM Ayurveda was finalized on Tuesday, 27 Jan 2026
IPO listing for KRM Ayurveda was on NSE on Thursday, 29 Jan 2026
KRM Ayurveda IPO LISTING GAINS
| Issue Price (adjusted) | 135.0 |
| Listing Open Price | 172.1 |
| Listing Close Price | 180.7 |
| Listing Gain% | 27.5% |
| Current Gain% | 123.7% |
KRM Ayurveda Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KRM Ayurveda Ltd. | 302 | 642.1 | 31.9 | 0.5 | 6.3 | 17.5 | 16.4 | 102.3 | 33 | 20.1 | 66.3 | 9.5 | 66.3 |
| Apollo Hospitals Enterprise Ltd. | 8945 | 128615.4 | 66.2 | 1.9 | 5.1 | 20.5 | 8.7 | 25420.1 | 15.6 | 1941.7 | 34.3 | 135 | 34.3 |
| Max Healthcare Institute Ltd. | 1070 | 104140.3 | 72.2 | 2.1 | 12.4 | 13.4 | 8.4 | 8536.1 | 18.8 | 1442.4 | 34.1 | 14.8 | 34.1 |
| Manipal Health Enterprises Ltd. | 678 | 89176 | 10.6 | 3.6 | 10520.5 | 25.8 | 892.3 | -16.2 | |||||
| Fortis Healthcare Ltd. | 955.2 | 72109.8 | 68.8 | 3.3 | 7.6 | 10.5 | 6.5 | 9178.5 | 16.9 | 1041.8 | 34.6 | 13.9 | 20.7 |
| Aster DM Quality Care Ltd. | 869.7 | 45061 | 141.4 | 882.1 | 9.2 | 8.5 | 4.8 | 4768.8 | 11.2 | 388.1 | -92.8 | 6.2 | 0.2 |
KRM Ayurveda INFORMATION ON IPO ISSUE
About KRM Ayurveda
KRM Ayurveda was incorporated on April 17, 2020. The company operates a network of six hospitals and five clinics across India and has an international presence through telemedicine consultations and sales. While it began as a kidney care provider, it now offers specialized treatments for multiple health disorders and trades in Ayurvedic medicines, oils, and supplements across wellness and healthcare segments
Object of the Issue
- Capital Expenditure for construction and development of telemedicine operational facilities
- Purchase of CRM software and hardware infrastructure
- Human resources
- Repayment/prepayment of loan
- To meet out the working capital requirements of the company
- To meet out the general corporate purposes
KRM Ayurveda - PROMOTERS
| Name |
|---|
| Puneet Dhawan |
| Tanya Dhawan |
KRM Ayurveda - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Puneet Dhawan | Managing Director |
| Tanya Dhawan | Non-Executive Director |
| Sanchit Hans | Whole Time Director |
| Vandana Gupta | Independent Director |
| Laxmi | Independent Director |
KRM Ayurveda Book Running Lead Manager
NEXGEN Financial Solutions Pvt. Ltd.
ipo@nexgenfin.com
KRM Ayurveda Registrar to the issue
Skyline Financial Services Private Limited
ipo@skylinerta.com
KRM Ayurveda Strengths
Skilled physicians
The company employs 31 qualified Ayurvedic physicians with BAMS degrees from recognized institutions, ensuring authentic and effective treatments. It is also supported by 59 certified Ayurvedic therapists trained in Panchakarma and other traditional therapies, following strict quality and patient safety standards
Centralized GMP-certified production
The company manufactures Ayurvedic medicines at a centralized GMP-certified facility compliant with the Drugs and Cosmetics Act and Schedule T standards. Strict quality controls, batch traceability, and regulatory oversight ensure product safety, efficacy, and compliance with domestic and international requirements
KRM Ayurveda Risks
Risks of contamination & adulteration
The manufacture and sale of Ayurvedic medicines involve risks such as contamination, adulteration, and regulatory non-compliance, which may affect the company’s reputation and financial performance. Evolving domestic and international regulations, along with potential safety concerns and import restrictions, could also impact operations and market access
Operational risks
The company’s operations face risks from regulatory changes, competition, economic factors, limited brand awareness, and misinformation about Ayurveda, which may affect performance and cash flows. Dependence on the availability and quality of herbal raw materials and the need to build brand trust in new regions could also disrupt operations and profitability
Competition
The healthcare and Ayurveda sectors are highly competitive, with established players having strong brands, wide networks, and greater resources. Intense competition, pricing pressure, and changing consumer and regulatory trends may affect the company’s ability to attract patients, maintain market share, and sustain profitability
IPO FAQs
The promoters of the company are Puneet Dhawan and Tanya Dhawan.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 128.0 - 135.0.
The IPO application opens on Jan 21, 2026 and closes on Jan 23, 2026.
The minimum lot size for the IPO is 2000. The maximum lot size for the IPO is 2000.
For all category investors, the minimum application amount for this IPO is Rs. 256,000.0, the maximum value for this IPO is Rs 270,000.0.
This IPO will be allotted on Jan 27, 2026.
The refund will be credited to your account on Jan 28, 2026.
The allotted shares will be credited to your demat on Jan 28, 2026.
KRM Ayurveda Ltd.’s shares listed on the stock exchanges on Jan 29, 2026.